

**Remarks**

This amendment is submitted along with a Request for Continued Examination.

**Amendments to the claims:**

Upon entry of this amendment, claims 1 and 22-43 will be pending in the application.

Claim 1 as now presented includes an amendment to the scope of the group R<sup>2</sup> to include additional substituted embodiments of a pyrido[3,2-b]thiazine group. Support for this amendment is found throughout the specification, including the original claims; page 3, line 18 to page 4, line 22; and page 6, lines 4-7, 24-25, 28, and 32 bridging to page 7, line 7.

Claims 2-6, 8-10, and 14-21 are being canceled (claims 7 and 11-13 being previously canceled).

New claims 22-43 are added. Support is found throughout the specification, including the claims as originally filed; page 3, line 18 to page 4, line 22; page 5, line 6 to page 8, line 25; Schemes V and VI (pages 18-20); and Examples 2, 10, 12, 13, 14, 18 and 19.

No new matter is added. Applicants respectfully request examination of each of the claims in this application.

**Conclusion:**

This amendment is made without disclaimer. Applicants reserve the right to pursue any canceled subject matter, any nonelected subject matter, and any other subject matter supported by the original application.

Entry of this amendment and favorable consideration of each of the pending claims is earnestly solicited. Should any issues remain to be resolved, the Examiner is invited to contact the undersigned at the telephone number shown below.

Respectfully submitted,



Loretta J. Sauermelch  
Attorney for Applicants  
Registration No. 37,347

GLAXOSMITHKLINE  
Corporate Intellectual Property – UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Tel: 610 270 6854  
Fax: 610 270 5090